Welcome to our dedicated page for Creative Med Technology Hldgs news (Ticker: CELZ), a resource for investors and traders seeking the latest updates and insights on Creative Med Technology Hldgs stock.
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is a pioneering biotechnology holding company dedicated to advancing regenerative medicine. Headquartered in Phoenix, Arizona, the company was incorporated in 1998 and operates as a subsidiary of Creative Medical Health, Inc. It leverages innovative stem cell research to develop therapeutic applications aimed at treating male and female sexual dysfunction, infertility, miscarriages, and related health issues.
The company's flagship product, marketed under the brand name CaverStem, specifically addresses erectile dysfunction (ED). CaverStem is offered to physicians to help patients suffering from ED through stem cell-based therapies.
In recent developments, Creative Medical Technology Holdings has seen notable success in the allogeneic cell therapy market. In Q4 2022, the company unveiled the development of AlloStem™, a cell line derived from human perinatal tissue, which incorporates a Master Cell Bank and a Drug Master File. The FDA has granted approval for the CELZ-201 program, allowing it to be used in early clinical trials for type 1 diabetes. The AlloStem™ line is also being employed in the company's StemSpine® procedure to treat chronic back pain, demonstrating significant reductions in narcotic usage and pain scores among treated patients.
Allogeneic cell therapy, a cornerstone of the company's research, involves using donated cells from a healthy individual to treat patients with otherwise intractable diseases. These therapies have shown great potential in providing curative options where traditional treatments have failed.
Creative Medical Technology is heavily involved in multiple clinical trials and continues to secure necessary regulatory approvals. The company’s financial health remains robust, with significant cash reserves and no long-term debt. Furthermore, Creative Medical Technology has built a strong intellectual property portfolio with over 68 patents and pending applications.
As of the latest updates, the FDA has cleared the company to proceed with a Phase 1/2 clinical trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for chronic lower back pain. The IRB approval has been received, paving the way for a placebo-controlled study that will assess the safety, efficacy, and tolerability of the treatment.
Overall, Creative Medical Technology Holdings is poised at the forefront of regenerative medicine, leveraging cutting-edge stem cell technologies to develop transformative therapies for chronic and debilitating conditions. The company’s ongoing clinical trials and strategic partnerships underline its commitment to medical innovation and improving patient outcomes globally.
Creative Medical Technology Holdings (NASDAQ: CELZ) announced positive two-year follow-up results from its StemSpine® pilot study, showcasing an 87% efficacy rate in treating chronic lower back pain with no serious adverse effects reported. The StemSpine® procedure utilizes a patient's own bone marrow aspirate, offering a promising non-surgical alternative. The company plans to publish this data and present it at upcoming conferences. Positive engagement with physicians is expected, particularly at the American Academy of Orthopaedic Surgeons conference in Chicago.
Creative Medical Technology Holdings (NASDAQ: CELZ) announced an exclusive agreement with Cervos Medical for the distribution of Marrow Cellution™ devices in urology, gynecology, and sexual dysfunction. This partnership grants Creative access to advanced regenerative therapies such as CaverStem® and FemCelz®. CEO Timothy Warbington highlighted the advantages of the agreement, including a strong supply chain and intellectual property. Cervos Medical's President emphasized the collaboration's potential to improve patient outcomes using innovative stem cell solutions.
Creative Medical Technology Holdings (NASDAQ: CELZ) announced its participation in the 34th Annual Roth Conference from March 13-15, 2022, in Dana Point, California. The company specializes in regenerative approaches in immunotherapy, urology, neurology, and orthopedics. Executives will be available for one-on-one meetings during the event. For more details or to register, visit the conference's registration page. The latest investor presentation can be found on the company's IR website.
Creative Medical Technology Holdings (NASDAQ: CELZ) announced the appointment of Sahil Nock as its Chief Commercial Officer, effective February 28, 2022. Mr. Nock brings over 15 years of healthcare leadership experience, previously serving as Head of US Commercial Marketing at Mentor, and has a strong background in marketing and business development. President and CEO Timothy Warbington expressed confidence that Nock will significantly impact the company's regenerative medicine programs, including CaverStem®, FemCelz®, and StemSpine®.
Creative Medical Technology Holdings announced a public offering of 3,875,000 shares and warrants at $4.13, aiming for gross proceeds of approximately $16 million. The stock will be listed on the Nasdaq under the ticker CELZ starting December 3, 2021, with closure expected around December 7, 2021. Roth Capital Partners is leading the offering, which includes a 45-day option for underwriters to purchase additional shares. This funding is pivotal for the company's focus on regenerative treatments in immunology, urology, neurology, and orthopedics.
Creative Medical Technology Holdings, Inc. (OTC-CELZ) announced a 1-for-500 reverse stock split, effective November 10, 2021, to facilitate its planned listing on The Nasdaq Capital Market. The reverse split will reduce outstanding shares from 1,226,141,742 to 2,452,348 without altering stockholder equity percentages. The temporary ticker symbol during this process will be CELZD, reverting to CELZ upon Nasdaq listing. The company aims to enhance its visibility and shareholder value through this strategic move.
Creative Medical Technology Holdings Inc. (OTC-CELZ) announced promising proof of concept data for its ImmCelz™ immunotherapy. This innovative product, utilizing a patent-pending 'ex vivo cell-free' reprogramming protocol, shows potential to reprogram patient immune cells effectively. The study, conducted at the University of Miami, indicates ImmCelz™ may enable rapid clinical translation, aiming to suppress harmful immune responses associated with autoimmune diseases. The company has filed an IND with the FDA related to stroke treatment. The autoimmunity market is valued in the billions, highlighting significant growth potential.
Creative Medical Technology Holdings (OTC – CELZ) announced the filing of a new patent for nanoparticles known as 'exosomes' derived from its MyeloCelz™ platform, aimed at treating type 1 diabetes. The patent includes the use of these exosomes in combination with other agents promoting immunological tolerance.
Notable experts, including Dr. Camillo Ricordi, praised the innovation, highlighting the potential to specifically target harmful T cells without affecting the body's defenses. This advancement could revolutionize treatment for type 1 diabetes and related autoimmune diseases.
Creative Medical Technology Holdings (OTC: CELZ), a biotechnology company, announced its partnership with Elite Med Listings Inc. on Sept. 16, 2021. This engagement aims to accelerate the adoption of their CaverStem® treatment, which focuses on regenerative medicine. Angela Chatterfield, CEO of Elite Med Listings, expressed confidence in the treatment's efficacy and safety after conducting thorough research. Timothy Warbington, CEO of Creative Medical Technology, looks forward to the collaboration, anticipating a significant business impact.
Creative Medical Technology Holdings, Inc. (CELZ) announced a definitive agreement for a private placement, raising approximately $3,788,000 from accredited institutional investors. The offering includes 15% Original Issue Discount Senior Notes totaling around $4,456,000, maturing on February 11, 2022. Additionally, the company will issue warrants for 157,184,354 shares of common stock, with an initial exercise price of $0.02835 for a five-year period. Roth Capital Partners is the sole placement agent, with the closing expected on August 11, 2021.
FAQ
What is the current stock price of Creative Med Technology Hldgs (CELZ)?
What is the market cap of Creative Med Technology Hldgs (CELZ)?
What does Creative Medical Technology Holdings, Inc. specialize in?
What is CaverStem?
What is AlloStem™?
What are the latest developments in Creative Medical Technology's clinical trials?
How does allogeneic cell therapy work?
What is the company's financial condition?
How is the company contributing to pain management?
What are some of the company's key partnerships?
Where is Creative Medical Technology Holdings located?
What is the ticker symbol for Creative Medical Technology Holdings, Inc.?
